The ~500% bioavailability improvement is a significant technical milestone that de-risks the AM formulation and supports future clinical trials. However, with a $4M market cap and no revenue, the stock is highly speculative. Monitor AM-003 results and any partnership or financing announcements. The cross-filing 20-F indicates ongoing dilution risk via shelf registration and equity purchase agreements.
Price Chart
Executive Summary
Galmed announced positive Phase 1 PK results for its oral Aramchol Meglumine (AM) formulation, showing ~500% bioavailability increase at 400mg vs. Aramchol Free Acid 300mg, enabling a once-daily lower dose. This is a meaningful pipeline de-risking event for a $4M market cap clinical-stage biotech, but the company remains pre-revenue with no near-term revenue catalyst.
Key Facts
- Phase 1 PK study (AM-001) showed 400mg AM granules for oral suspension increases bioavailability by ~500% vs. 300mg AA tablets.
- 200mg AM showed ~3-fold bioavailability increase vs. 300mg AA.
- Transition to once-daily 400mg AM dose enables GMP clinical batch production, solidifies IP protection, and may reduce drug CoGs by ~50%.
- Additional PK study (AM-003) comparing AM 400mg tablets once daily vs. AA 300mg twice daily is ongoing.
- Company is a clinical-stage biopharma with $4M market cap, pre-revenue, and no approved products.
Financial Impact
No financial figures provided; potential cost of goods reduction of ~50% and improved patient compliance upon commercialization, but no revenue or earnings data.
Risk Factors
- Pre-revenue clinical-stage company with no approved products and high cash burn.
- Ongoing dilution risk from existing shelf registration and standby equity purchase agreement.
- Clinical and regulatory uncertainty for MASH and GI oncology indications.
- Low market cap and liquidity risk; stock may be volatile on news flow.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-022873 |
| Exhibit: ex99-1.htm | 0001493152-26-022873 |
| Document: 0001493152-26-022873-index-headers.html | 0001493152-26-022873 |
| Document: 0001493152-26-022873-index.html | 0001493152-26-022873 |
| Document: 0001493152-26-022873.txt | 0001493152-26-022873 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 6-K | $4.63 $3.63 | ▼ −21.71% | ▼ −21.37% | — |
Sep 4, 2026 7w ago | EFFECT | $3.88 $4.63 | ▼ −19.33% | ▼ −20.54% | — |
Sep 3, 2026 7w ago | 6-K | $3.88 $4.63 | ▲ +19.33% | ▲ +20.54% | — |
Sep 2, 2026 7w ago | 6-K | $3.92 $4.63 | ▲ +18.11% | ▲ +19.26% | — |
Aug 19, 2026 9w ago | 6-K | $4.77 $4.33 | ▼ −9.22% | ▼ −8.84% | — |
Aug 17, 2026 10w ago | 6-K | $0.5134 | awaiting T+5 | — | — |
Jul 28, 2026 13w ago | 6-K | $0.5340 $0.5754 | ▲ +7.75% | ▲ +3.64% | — |
Jul 16, 2026 14w ago | 6-K | $0.5501 $0.5530 | ▲ +0.53% | ▲ +2.20% | — |
Jun 22, 2026 18w ago | 6-K | $0.5641 $0.5709 | ▲ +1.21% | ▲ +1.66% | — |
Jun 8, 2026 20w ago | 6-K | $0.4693 $0.6160 | ▲ +31.26% | ▲ +29.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers